Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
IPO Year: 2006
Exchange: NASDAQ
Website: vandapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $18.00 | Buy | H.C. Wainwright |
| 7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
DEFA14A - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
DEF 14A - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
10-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g
WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysanti™ (milsaperidone) has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application. Bysanti™ is a new chemical entity, which was initially identified as an active metabolite of iloperidone. Vanda has discovered that milsaperidone, when administered orally, qu
Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference
WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (NASDAQ:VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the approvability of tradipitant for gastroparesis. Rather than take accountability, FDA bureaucrats identify a new scapegoat: newly appointed Commissioner, Dr. Martin Makary, and reductions in force. FDA last night represented to a federal court that the April 1 reduction in force is partially to blame for the Center for Drug and Evaluation and Research's delay of at least 6 more months to p
WASHINGTON, April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025. The following will be presented: April 9, 2025 Presentation Title: "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics This poster de
WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti™ (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti™. Bysanti™ is a new chemical entity that belongs in the class of atypical antipsychotic drugs. Bysanti™ is believed to achieve its therapeutic effect by interacti
WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). In 1886, Jean-Martin Charcot, Pierre Marie, and Henry Tooth independently describ
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023Full year 2025 revenue expected to grow to $210 to $250 millionPsychiatry portfolio revenue expected to grow to greater than $750 million in 2030Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025HETLIOZ® MAA for Smith-Magenis syndrome submitted in Q4 2024Tradipitant NDA for motion sickness submitted in Q4 2024Imsidolimab BLA in generalized pustular
Conference Call and Webcast to Follow WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, February 13, 2025, during which management will discuss the fourth quarter and full year 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ:ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully co
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00
Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously
B of A Securities initiated coverage of Vanda Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Citigroup reiterated coverage of Vanda Pharmaceuticals with a rating of and set a new price target of $18.00 from $14.00 previously
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g
Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023Full year 2025 revenue expected to grow to $210 to $250 millionPsychiatry portfolio revenue expected to grow to greater than $750 million in 2030Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025HETLIOZ® MAA for Smith-Magenis syndrome submitted in Q4 2024Tradipitant NDA for motion sickness submitted in Q4 2024Imsidolimab BLA in generalized pustular
Conference Call and Webcast to Follow WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, February 13, 2025, during which management will discuss the fourth quarter and full year 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash rangesFanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023Fanapt® long acting injectable program expected to be initiated in Q4 2024Milsaperidone NDA for schizophrenia and bipolar I disorder expected to be submitted in early 2025; initiation of major depressive disorder program expected in Q4 2024PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024PONVORY® IND applications for psoriasis and ulcerative colitis expected to be submitted in Q4 2024Tradipi
Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2555000. The
Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023Financial Guidance reinstated for Full Year 2024Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 18, 2024Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024WASHINGTON, July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational res
Conference Call and Webcast to Follow WASHINGTON, July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 1278669. The c
Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023Cash increase of $5.9 million in Q1 2024 to $394.1 millionFanapt® approved for the acute treatment of bipolar I disorder; commercial launch expected in Q3 2024Milsaperidone NDA for schizophrenia and bipolar disorder expected to be submitted in early-2025PONVORY® commercial launch expected in Q3 2024Tradipitant NDA review for gastroparesis ongoing, PDUFA date of September 18, 2024Tradipitant second Phase III motion sickness study results expected in Q2 2024; NDA expected to be submitted in Q4 2024WASHINGTON, May 8, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and op
Conference Call and Webcast to Follow WASHINGTON, April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 8, 2024, during which management will discuss the first quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2594340. The conferen
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin